Surf Bio, Inc. is excited to announce a remarkable funding milestone with an injection of $1,600,000 in new capital that will accelerate our mission to transform the delivery of antibodies and biologics to patients around the world. As a pioneering preclinical biopharmaceutical company, Surf Bio is redefining healthcare by integrating our cutting-edge Surf SnapShot™ technology into therapeutic development. This funding boost will empower us to advance our research and critical preclinical studies, further developing the innovative formulations that enable subcutaneous delivery of monoclonal antibodies at concentrations exceeding 600 mg/mL. With the unique capability of delivering doses over 1,000 mg in a single, standard autoinjector shot, our ultra-high concentration formulations set a new standard in patient-friendly treatment protocols.
The capital raised will be instrumental in optimizing Surf SnapShot™ and our proprietary polymer platform, providing a robust foundation for streamlined delivery processes that promise improved efficacy and enhanced patient compliance. Our team is dedicated to overcoming longstanding challenges in biologic therapies by ensuring that high dosing can be achieved safely and comfortably, thus broadening access to life-changing treatments. Beyond the laboratory, this funding supports the strategic expansion of our development pipeline and positions Surf Bio at the forefront of therapeutic innovation. We are thrilled to forge ahead with our mission, confident that these investments will not only expedite our journey from preclinical to clinical milestones but also profoundly impact patient care in the evolving landscape of biopharmaceuticals. For further details about our technology and vision, please visit www.surf.bio.
.png&w=3840&q=75)
